Citable company snapshot
Insmed Incorporated's latest SEC-sourced 2026-06-30 period shows $425.49M in revenue and $-13.24M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 30, 2026 | $425.49M | $305.96M | +39.1% |
| Gross Profit | Sep 30, 2020 | $33.02M | $32.55M | +1.5% |
| Operating Income | Jun 30, 2026 | $-1.55M | $-153.32M | +99.0% |
| Net Income | Jun 30, 2026 | $-13.24M | $-163.56M | +91.9% |
| Operating Cash Flow (computed) | Jun 30, 2026 | $-88.83M | $-222.74M | +60.1% |
| Free Cash Flow (computed) | Jun 30, 2026 | $-95.09M | $-226.22M | +58.0% |
Source: SEC EDGAR financial statements; period Jun 30, 2026; filed Aug 6, 2026; accession 0001104506-26-000041.
INSM company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.
Continue research
Follow same-sector companies and source explainers connected to the overview view.
A factual guide to market capitalization, shares outstanding, public float, and why share-count definitions matter.
A factual guide to dividends, share repurchases, and how companies can return capital to shareholders.
A factual guide to book value, tangible book value, and balance-sheet net worth measures.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.